The pharmaceutical landscape for immunological conditions may be on the verge of a major shift. Biogen Inc.’s new collaboration with Dayra Therapeutics marks a strategic move into the growing field of oral macrocyclic peptides.

Biogen is investing $50 million upfront, with more milestone payments possible as the program advances. The deal structure shows strong confidence in this emerging drug class and its potential impact on chronic inflammatory and autoimmune diseases.

For patients, the implications could be significant. Oral macrocyclic peptides may improve treatment adherence and therapeutic outcomes, and could eventually challenge the current dominance of injectable biologics in immunology.

NX210c is emerging as one of the more scientifically grounded preclinical candidates in spinal cord injury research. Spinal cord injury, often referred to as SCI, remains a devastating neurological condition that affects hundreds of thousands of people worldwide every year.

Patients frequently experience permanent motor, sensory, and autonomic deficits below the site of injury. Despite decades of intensive research, pharmacological therapies that reliably restore motor function after SCI remain limited, and most treatment strategies still focus on surgical intervention, acute stabilization, and long-term rehabilitation rather than true neurological repair.

Against this backdrop, NX210c has attracted attention for its multi-dimensional effects in animal models of SCI. Derived from thrombospondin-related biology, NX210c has demonstrated improvements in motor function, tissue preservation, and neuronal signaling in preclinical studies.